BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38766796)

  • 1. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
    Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
    Suppadungsuk S; Phitakwatchara W; Reungwetwattana T; Pathumarak A; Phakdeekitcharoen B; Kitiyakara C; Srisuwarn P; Davenport A; Nongnuch A
    ESMO Open; 2022 Feb; 7(1):100351. PubMed ID: 34953401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
    Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
    PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
    Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
    Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
    Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
    Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
    Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
    Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Renal Outcomes after Cisplatin Treatment.
    Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
    Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
    Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer.
    Driessen CM; Uijen MJ; van der Graaf WT; van Opstal CC; Kaanders JH; Nijenhuis T; van Herpen CM
    Head Neck; 2016 Apr; 38 Suppl 1():E1575-81. PubMed ID: 26614010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
    Yamamoto Y; Watanabe K; Tsukiyama I; Matsushita H; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2015 Apr; 35(4):2199-204. PubMed ID: 25862878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
    Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
    BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Effect of Premedication with Intravenous Magnesium on Renal Dysfunction in Preoperative Cisplatin-Based Chemotherapy for Esophageal Cancer.
    Kubo Y; Miyata H; Sugimura K; Shinno N; Ushigome H; Yanagimoto Y; Takahashi Y; Yamamoto K; Nishimura J; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
    Oncology; 2019; 97(6):319-326. PubMed ID: 31553989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.
    Moon HH; Seo KW; Yoon KY; Shin YM; Choi KH; Lee SH
    World J Gastroenterol; 2011 Aug; 17(30):3510-7. PubMed ID: 21941418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.